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Background: Despite the high prevalence and global impact of knee osteoarthritis (KOA), current treatments are
palliative. No disease modifying anti-osteoarthritic drug (DMOAD) has been approved. We recently demonstrated
significant involvement of uric acid and activation of the innate immune response in osteoarthritis (OA) pathology
and progression, suggesting that traditional gout therapy may be beneficial for OA. We therefore assess colchicine,
an existing commercially available agent for gout, for a new therapeutic application in KOA.
Methods/Design: COLKOA is a double-blind, placebo-controlled, randomized trial comparing a 16-week treatment
with standard daily dose oral colchicine to placebo for KOA. A total of 120 participants with symptomatic KOA will
be recruited from a single center in Singapore. The primary end point is 30% improvement in total Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score at week 16. Secondary end points include
improvement in pain, physical function, and quality of life and change in serum, urine and synovial fluid biomarkers
of cartilage metabolism and inflammation. A magnetic resonance imaging (MRI) substudy will be conducted in 20
participants to evaluate change in synovitis. Logistic regression will be used to compare changes between groups
in an intention-to-treat analysis.
Discussion: The COLKOA trial is designed to evaluate whether commercially available colchicine is effective for
improving signs and symptoms of KOA, and reducing synovial fluid, serum and urine inflammatory and biochemical
joint degradation biomarkers. These biomarkers should provide insights into the underlying mechanism of
therapeutic response. This trial will potentially provide data to support a new treatment option for KOA.
Trial registration: The trial has been registered at clinicaltrials.gov as NCT02176460. Date of registration:
26 June 2014.
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Knee osteoarthritis (KOA) is one of the five leading
causes of disability among noninstitutionalized adults
[1]. The risk of mobility disability (defined as needing
help walking or climbing stairs) attributable to OA alone
is greater than any other medical condition in people
aged 65 and over [2]. In the World Health Organization
Global Burden of Disease Study of 21 epidemiological
regions across the world, from 1990 to 2010 there was a
26.8% increase in the burden of KOA as measured by
years lived with disability per 100,000 persons [3]. The
global prevalence of KOA will continue to rise in tan-
dem with increases in the prevalence of obesity and lon-
gevity worldwide. Despite the high prevalence and global
impact of KOA, current treatments are limited to pallia-
tive measures broadly focused on analgesia, and when
this fails, surgical knee replacement. Given its frequency,
associated disability and societal cost, patients with KOA
are in urgent need of effective treatment that reduces
pain and symptoms, and slows progression of OA. There
are a number of agents, like glucosamine sulfate, chon-
droitin sulphate, diacerin, doxycycline and licofelone
that have demonstrated structural modifying capabilities
in clinical trials [4]. Overall, these trials did not report a
favorable profile with respect to side effects, no con-
comitant symptomatic relief or failed to demonstrate the
structural modifying endpoints as required by the Food
and Drug Administration (FDA) [5].
In a KOA cohort without clinical evidence or self-
report of gout, we found a significant correlation of syn-
ovial fluid uric acid with radiographic and scintigraphic
measures of OA severity [6]. We also observed strong
correlations of radiological OA severity and synovial
fluid uric acid with synovial fluid interleukin (IL)-18 and
IL-1β; these two cytokines are classically produced dur-
ing gout attacks by innate immune system activation
mediated by uric acid crystal-induced inflammasome as-
sembly in macrophages. These results strongly support
the involvement of uric acid and the innate immune sys-
tem in OA pathology and progression. The pain and
symptom relieving effects of colchicine for KOA have
been demonstrated in three small, but well-performed
human randomized controlled trials (RCTs) [7-9];
however, the mechanism of action of colchicine in KOA
has never been evaluated. We hypothesize that colchi-
cine will block inflammasome-mediated inflammation,
thereby improve the signs and symptoms of OA, and re-
duce synovial fluid serum and urine inflammatory and
biochemical joint degradation biomarkers. We propose
a randomized controlled trial (RCT) of colchicine, an
agent traditionally used for the treatment of gout, to
examine the effects on signs and symptoms of KOA and
to evaluate the mechanism of action of this therapy in OA




The trial is designed to address the following objectives:
1. To determine whether daily oral colchicine at
standard clinical doses (0.5 mg two times daily),
compared to placebo, can decrease the pain of
symptomatic KOA and improve function when used
in addition to the patient’s current stable analgesic
regimen.
2. To evaluate the mechanism of action of colchicine
for reducing KOA signs and symptoms through
analyses of synovial fluid, serum, and urine
biomarker profiles; characterizing the state of joint
tissue metabolism (through joint degradation and
synthesis markers), inflammatory mediators of the
innate immune system and the NACHT-LRR-PYD-
containing protein-3 (NALP3) inflammasome before
and after colchicine treatment compared to placebo.
Study design
COLKOA is a single center, double-blind randomized
placebo-controlled clinical trial, conducted at Singapore
General Hospital, comparing colchicine with placebo in
patients with primary KOA. The study protocol was ap-
proved by the SingHealth Centralized Institutional Re-
view Board (ref. CIRB2012/659/E), and informed consent
will be obtained from all participants before the start of
the study. A clinical trial certificate (CTC1300061) was
obtained from the Singapore Health Sciences Authority.
Participant selection and eligibility criteria
Adults aged 21 to 79 with symptomatic KOA will be
recruited through advertisements, referrals from primary
health care, orthopedic and internal medicine specialists.
Study inclusion requires the following: symptomatic KOA
meeting American College of Rheumatology (ACR) cri-
teria [10]; radiographic criteria for KOA with Kellgren-
Lawrence (KL) stage of ≥2 in at least one knee at
screening [11]; symptomatic KOA defined as a positive
response to the question, “Do you have pain, aching or
stiffness of the knee on most days of the past month;
and a score of ≥40 out of 100 on a visual analog scale
(VAS) for knee pain. Further details regarding inclusion
and exclusion criteria are summarized in Table 1. We
also excluded subjects on current treatment with drugs
known to inhibit cytochrome 450 (CYP3A4) and/or P-
glycoprotein (P-gp) (see Additional file 1: Table S1) [12]
that increase the risk of colchicine-induced toxic effects.
Current treatment with these drugs mandates exclusion
from the study until the drug is discontinued >14 days
Table 1 Inclusion and exclusion criteria for colchicine effectiveness in symptom and inflammation modification in knee
osteoarthritis (COLKOA)
Inclusion
Criteria • Symptomatic KOA meeting American College of Rheumatology (ACR) criteria
• Radiographic criteria for KOA with Kellgren-Lawrence (KL) stage of≥ 2 in at least one knee
• Response positive to the question "do you have pain, aching or stiffness of the knee on most days of the past month
• Score of≥ 40 out of 100 on a visual analogue scale (VAS) for knee pain
• Age 21 years or above
• Male and female subjects and all ethnicities included
• Patients to agree to avoid consuming grapefruit and grapefruit juice while using colchicine
• Ability to provide informed consent
Exclusion
Criteria • Exposure to a corticosteroid (either parenteral or oral) within 3 months prior to the study enrolment
• Knee arthroscopic surgery within 6 months prior to the study enrolment
• Known history of avascular necrosis, inflammatory arthritis (e.g. Rheumatoid Arthritis), Paget's disease, joint infection, periarticular
fracture, neuropathic arthropathy, reactive arthritis, or gout involving the knee
• Contraindication to arthrocentesis (warfarin use, bleeding disorder, skin rash or skin infection of signal knee)
• Knee joint replacement in either knee
• History of podagra, active gout or treatment for gout
• Pregnancy or lactation - women of childbearing potential will have serum pregnancy testing (ßHCG) at time of entry prior to any
imaging studies (radiographic or MRI); female subjects of childbearing potential must agree to use some form of contraception dur-
ing the 16 week trial and for 1 week after the end of the trial (over 6 half-life equivalents)
• Renal failure with serum creatinine > 150 mmol/L (1.7 mg/dL);
• Hepatic impairment defined by serum alanine transaminase (ALT) above the upper limit of normal (ULN) for the clinical laboratory
performing the screening test
• Muscle impairment defined by elevated serum creatine phosphokinase (CPK) above the ULN for the clinical laboratory performing
the screening test
• Personnel directly affiliated with this study or their immediate family members (defined as a spouse, parent, child or sibling,
whether biological or legally adopted)
• Current enrollment in or discontinued within the last 30 days from a clinical trial involving an off-label use of an investigational
drug or device, or are concurrently enrolled in any other type of medical research judged to be scientifically or medically incompat-
ible with this study
• Inability to understand and cooperate with the investigators or to give valid consent;
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Table 1 Inclusion and exclusion criteria for colchicine effectiveness in symptom and inflammation modification in knee
osteoarthritis (COLKOA) (Continued)
• Contraindication for magnetic resonance imaging (MRI) - this is exclusion only for the subset of individuals selected for this im-
aging procedure
• Anticipation of need for joint replacement within 4 months of the start of the intervention
• Current treatment with drugs known to inhibit CYP3A4 isoforms and/or P-glycoprotein (P-gp) that increase the risk of colchicine-
induced toxic effects
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moderate CYP3A4 inhibitor, and colchicine toxicity has
been reported in a patient consuming it concomitantly,
participants in this study have to agree to avoid con-
suming grapefruit and grapefruit juice during the course
of the RCT. The study design and schedule are summa-
rized in Figure 1 and Table 2.
Treatment assignment and allocation concealment
The US Food and Drug Administration (FDA) and
Singapore Health Sciences Authority approved colchicine
for the treatment of acute flare-ups of gout and for
chronic treatment of Familial Mediterranean Fever
(FMF). Colchicine is available as a generic medication
in Singapore. Generic colchicine (SIN 12490P) are
repackaged for use in this study. Identical placebo tab-
lets are produced to ensure allocation concealment.
Upon production, study medications are packaged and re-
labeled into numbered bottles by designated pharmacists
according to the randomization list prepared by the trial
biostatistician. Participants are randomly assigned in
blocks of ten to the intervention arm or the placebo
arm in a 1:1 ratio.
Blinding
Investigators and participants will remain blinded
throughout the trial. Emergency unblinding will be
allowed in limited situations that are perceived to
impact the safety of study participants. Code-break
envelopes for the full randomization schedule will be
maintained by the designated biostatistician.
Intervention
Participants with symptomatic KOA will be randomized
to oral colchicine 0.5 mg or placebo twice daily for
16 weeks. Participants are permitted to remain on their
baseline adjunctive therapy, including topical analgesics,
supplements, nonsteroidal anti-inflammatory drugs
(NSAIDs) without changes of drug and dosage for the
duration of the study. They will also be allowed the use
of paracetamol <2 g/day as rescue analgesia. Pill count-
ing at the end of the study will be conducted to deter-
mine the amount of study drug and rescue medicineutilized over the course of the 16-week study. Participants
are asked not to start any new pharmacological and
nonpharmacological therapies for their KOA, including
new topical medications, acupuncture, exercise class or
physiotherapy, for the duration of the study. Detailed in-
formation on existing or new medication use for knee
symptoms is collected at weeks 1, 4 and 16.
Clinical variables
Clinical variables include age, sex, ethnic group, educa-
tional level, history of major joint injuries, history of
knee joint surgery, comorbidities, and current medica-
tions and dosage, presence or absence of pain in other
joints; severity of pain of the signal knee and non-signal
knee at rest and on movement. Physical examination
will include measurement of joint alignment [13] and
range of motion of the signal knee. The signal knee is
defined as the one meeting entry criteria; if both knees
meet entry criteria, the more symptomatic knee at base-
line will be considered the signal knee; if symptoms are
equal on both sides, the dominant knee will be
designated the signal knee. Patient reported outcome
measures include Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) [14],
Health Assessment Questionnaire (HAQ) [15] and
Outcome survey short-form 36 version 2 (SF36v2)
[16]. All clinical variables are obtained at baseline and
week 16, the end of the study.
Biospecimen collection
Prior to randomization, participants will have simultan-
eous blood and urine collection and joint fluid aspiration
from both knees by an experienced rheumatologist. Blood
samples are obtained at least 2 hours post-prandial, and
urine samples are obtained from the second void of the
morning. The blood and urine sample collection is re-
peated at week 1, week 4 and the end of study (week 16).
Synovial fluid collection is repeated at the end of study.
Synovial fluid is aspirated directly from each knee by a
20-gauge needle. If no fluid is obtained, 10 ml of sterile
saline is injected into the joint and the fluid aspirated
after gentle compression of the knee. The dilution
factor of the lavage fluid (that obtained by saline
Figure 1 Flow chart of the study. ID, identification; MRI, magnetic resonance imaging; bid, twice per day.
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urea method [17].
Soluble biomarker variables
In addition to uric acid, four types of soluble bio-
markers will be assessed: inflammasome associated
biomarkers, biomarkers of oxidant stress, other inflam-
matory biomarkers, and cartilage degradation bio-
markers. The serum (s) and synovial fluid (sf ) markers
to be measured by category are the following: s/sf uricacid; inflammasome associated (s/sf IL-1 ß , IL-18, tumor
necrosis factor (TNF)α, caspase-1, Toll-like receptor
(TLR)-2, and TLR-4); oxidative stress (s/sf xanthine oxi-
dase, allantoin, inorganic pyrophosphate (PPi) and sf car-
bonyl content); other inflammatory markers (sCD163
which potentially indicative of macrophage activation, s/sf
matrix metalloproteinase (MMP)3, IL-6, and high sensitiv-
ity C-reactive protein (hs-CRP)); cartilage degradation
markers (sf glycosaminoglycan fragments and sf C-
terminal crosslinked telopeptide type II collagen (CTXII)).
Table 2 Schedule of assessment and data collection
Screening visit Allocation Post allocation













Screening knee X-ray x
Screening blood test * x
Physical Examination x x x x x
Interventions:
Colchicine 0.5 mg bid Start here End here
Placebo 1 tablet bid Start here End here
Assessments:
Physical Examination x x x x x
Full blood count x x
Renal function test x x x x
Liver function test x x x x
Uric acid x x x x
CPK x x x x
βHCG (for women with child bearing potential) x
Blood biomarkers collection x x x x
Urine biomarkers collection x x x x
Blood for pharmcogenomic x
Colchicine level x x x x
Both knees aspiration x x
Knee X-ray (both sides) x
MRI of signal knee ǂ (for 20 subjects only) x
Adverse event enquiries x x x x
Enquiries to compliance to usual medications for
knee
x x x x
Clinical data collection x x
Pain score enquiries (signal knee) x x x x




*(FBC, renal function, liver function, uric acid, CPK, βHCG for women with child bearing potential); ǂ: For ten colchicine treated and ten placebo treated
participates, randomly assigned; CPK, creatine phosphokinase; βHCG, β-human chorionic gonadotropin; MRI, magnetic resonance imaging; X-ray, radiography;
WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; HAQ, Health Assessment Questionnaire; SF36v2, Medical Outcome Short Form 36
version 2.
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biomarker concentrations for any dilution introduced by
lavage.
Magnetic resonance imaging variables
The specific subjects selected for MRI were pre-specified,
without knowledge of their clinical data, as the 6th to 25th
participants being randomized to colchicine and placeborespectively. This choice ensured, based on block
randomization, that half (n = 10) would be colchicine-
treated and half (n = 10) placebo-treated. The MRI exami-
nations consist of a standardized set of acquisitions with
specific positioning and localization requirements. The
MRI imaging will be performed using a 3 Tesla Siemens
Skyra (2012, Simens, Erlangen, Munich, Germany) with
the signal knee immobilized in a 15 Channel Transmit/
Leung et al. Trials  (2015) 16:200 Page 7 of 11Receive Knee coil. The intravenous contrast medium
used will be Dotarem, 0.5 mmol/ml (Gadoteric Acid,
Guerbet, France) with a maximum administered volume
of 10 ml. The whole knee joint will be scored by an expe-
rienced musculoskeletal radiologist blinded to clinical
details of participants, using the Boston Leeds Osteo-
arthritis Knee Score (BLOKS) [18]. At the time of the
screening evaluation, knee radiography of all patients
will be performed with the SynaFlexor platform and
variable beam angle as previously described [19] to
optimize images for serial joint space width measure-
ments in the event of any future long-term follow-up of
the participants in this trial.
Safety evaluation
Safety and tolerability of treatment will be assessed at
weeks 1, 4 and 16. Safety is assessed by identifying ad-
verse events (AEs) during treatment using open-ended
questions and a checklist that includes diarrhea, myalgia
and muscle weakness, and physical examination of muscle
tenderness and muscle strength. Laboratory assessments
include renal and liver function tests and creatine phos-
phokinase (CPK). All patients are given a 24-hour emer-
gency contact number for enquiries should there be
adverse events. Patients who are noted to have significant
adverse events at week 4, such as myalgia or an increase
in arthralgia will be contacted by the study team via tele-
phone and arrangements will be made for extra outpatient
visits as clinically indicated. Adverse events are recorded
at each visit and up to 16 weeks and are analyzed for their
seriousness, intensity and causal relationship with treat-
ment and outcome according to the National Institutes of
Health standardized Common Terminology Criteria [20].
A Data Safety and Monitoring Board consisting of two in-
dependent rheumatologists and one biostatistician will
monitor the study biannually and review reportable ad-
verse events and be responsible for the decision to con-
tinue the study in the event of a drug related serious
adverse effect.
Outcomes
The primary endpoint will be 30% improvement in total
WOMAC score of the signal knee. Secondary endpoints
include change in WOMAC pain score and physical
function score, HAQ, SF36v2 and the quantity of rescue
medication used. Other secondary endpoints include
treatment response defined by the Outcome Measures
in Rheumatology Clinical Trials and Osteoarthritis Re-
search Society International (OMERACT-OARSI) 2004
criteria [21], wherein participants are classified as re-
sponders if the pain or physical function score is de-
creased by ≥30% and by at least 20 mm on the VAS.
Other endpoints include statistically significant (P <0.05)
treatment related change in MRI detected synovitis andcartilage morphology and decline in synovial fluid IL-18,
IL-1β, or TNF-α. We will also explore the polymor-
phisms of multidrug resistance gene-1 (MDR-1) genes
(1236C > T, 2677G > A/T, 3435C > T) that encodes P-gp
and cytochrome CYP3A4*1B, CYP3A5*3 and CYP3A5*6;
corresponding to treatment response to colchicine and
drug levels in serum and synovial fluid.
Sample size estimation
Based on the results of an existing RCT [8], we expect
to achieve a 30% improvement rate in WOMAC in 57%
and 23% of the subjects in the colchicine and placebo
groups, respectively. To detect this difference at a sig-
nificance level of 5% (P <0.05) and 80% power, 32 partic-
ipants per group (64 total) will be required; for 90%, 42
participants per group (84 total) will be required. We
therefore plan to enroll 120 participants for this trial to
insure 90% power even with a dropout rate of up to 30%.
Statistical analysis
Analyses will be conducted using R 3.1.1 (R Core Team,
Vienna, Austria). Throughout, P values <0.05 will be
considered statistically significant. Analyses will be per-
formed from an intention-to-treat perspective. The pro-
portion of participants achieving the primary endpoint,
30% improvement in total WOMAC at week 16, will be
compared between the colchicine and placebo groups
using a chi-squared test. Participants who do not have a
follow-up WOMAC will be assumed to not have a ≥30%
improvement in WOMAC, thereby making the analysis
conservative. Additionally, WOMAC score, as well as
other secondary endpoints, for each patient across time
will be analyzed in the context of generalized estimating
equations (GEE) models with sandwich estimators of
variance to appropriately handle the dependency among
multiple observations on the same patient. While
randomization ensures approximate balance with re-
spect to known and unknown confounders, this GEE
analysis will be adjusted by potential confounders in-
cluding age, gender, and baseline clinical covariates.
These adjustment confounders will be selected by step-
wise variable selection with the Akaike information cri-
terion (AIC). While attrition is not expected to be high,
the GEE model is able to utilize all nonmissing data
while remaining unbiased so long as the pattern of data
missingness, conditional on observed outcomes and co-
variates, does not depend on the values of the missing
data, that is, the data must be missing at random
(MAR). If it is discovered that the pattern of data miss-
ingness depends on covariates not included in the ad-
justed model, these variables may also be incorporated
so that the MAR assumption is satisfied [22]. Variables
associated with the pattern of data missingness would
be incorporated using a forward stepwise approach with
Leung et al. Trials  (2015) 16:200 Page 8 of 11a P value <0.05 entry criterion. Secondary endpoints will
be analyzed in the context of GEE models, depending
on whether the endpoint is categorical or continuous,
with a fixed effect for treatment. Secondary endpoints
that are measured on both of a patient’s knees will add-
itionally include fixed effects for KOA and KOA by
treatment interaction. Secondary analyses will also be
supplemented by covariate adjusted tests, where covari-
ates will once again be selected using stepwise variable
selection with AIC. To evaluate the mechanism of ac-
tion of colchicine for reducing knee OA signs and
symptoms, the change from baseline to 16 weeks (at
study end) in synovial fluid, serum, and urine biomarker
profiles will be compared between oral colchicine and
placebo treatment. The relationship between response
(≥30% improvement in WOMAC) and change from
baseline to 16 weeks (at study end) in synovial fluid,
serum, and urine biomarker profiles will be assessed in
the context of a logistic regression model. Various ex-
ploratory statistical models and analyses such as struc-
tural equation modelling and factor analysis will be
performed to further elucidate the mechanisms of ac-
tion of colchicine.
Discussion
This RCT is proposed at a time when effective treat-
ments for OA are urgently needed. It is well grounded
in a strong biological rationale and a strong clinical ra-
tionale with the several small preceding RCTs of colchi-
cine for KOA. This proposed RCT is two- to threefold
larger than any of the existing trials allowing greater
power to test and validate the clinical effectiveness of
colchicine for knee OA signs and symptoms. This RCT
will break new ground by exploring the mechanism of
action of colchicine in knee OA through testing the
ability of colchicine to inhibit inflammasome activation
in OA. Finally and importantly, this trial can serve as a
valuable paradigm for a subsequent larger longer-term
multicentered RCT with long-term radiographic and
MRI follow-up to evaluate the effects of colchicine to
slow or halt progression of OA structural deterioration
in addition to evaluating its long-term effects on OA
symptoms and function.
The association of uric acid and OA has long been ob-
served [23], although not statistically significant after
controlling for body mass index in cohort studies
[24-26]. One study noted that acute attacks of gout co-
incided with the presence of clinical OA in the same
joint suggesting that OA may facilitate the localized de-
position of monosodium urate (MSU) crystals [27]. In a
recent study of cadaveric ankles (talus surface only),
crystals were strongly associated with cartilage lesions -
overall 92% of cartilage lesion cases were associated
with crystal deposition of which 67% and 33% wereMSU and calcium pyrophosphate dihydrate (CPPD)
crystals, respectively [28]. Apart from the morphological
changes, crystal deposition in joints was also associated
with immunohistochemical changes including superfi-
cial zone protein and collagen X that is associated with
cartilage degeneration and repair. A study of human
chondrocyte explants also demonstrated that MSU crys-
tals inhibit chondrocyte viability and function [29]. In a
study among OA subjects without clinical gout, we re-
cently demonstrated a strong positive association be-
tween synovial fluid uric level, IL18 and IL1β and OA
severity as measured by imaging [6]. This suggested that
MSU crystals may contribute both to the initiation and
propagation of cartilage degradation. We hypothesize in
OA that the degradation of cartilage extracellular
matrix components may facilitate the nucleation of
MSU crystals, forming microparticles that trigger the
innate immune response via activation of dendritic cells
and macrophages with subsequent priming of T cells
(Figure 2).
This new conception of the pathogenesis of OA has
very important treatment implications; it suggests that
existing therapies for gout may be of benefit in OA. One
such long-standing therapy for gout, colchicine, effect-
ively suppresses the innate immune response at various
levels; this makes colchicine a strong candidate as an
effective treatment. At micromolar concentrations (from
0.5 μM to 5 μM) colchicine has several anti-inflammatory
mechanisms of action: it suppresses activation of the MSU
crystal-induced NALP3 inflammasome, and it suppresses
IL-1β processing and release and neutrophil recruitment.
It is important to realize that colchicine preferentially ac-
cumulates in leukocytes. The concentration in neutrophils
may be more than 16 times the peak concentration in
plasma. It is possible that a continuous low prophylactic
dose of colchicine can achieve an intracellular concentra-
tion in macrophages high enough to inhibit NALP3
inflammasome activation that is triggered by danger sig-
nals formed after release of uric acid and cartilage extra-
cellular matrix fragments from degrading cartilage in OA.
At much lower (nanomolar) concentrations, colchicine
has additional mechanisms of action: it blocks the re-
lease of a crystal-derived chemotactic factor from neu-
trophil lysosomes; and it blocks neutrophil adhesion to
endothelium. In an in vivo study colchicine inhibits MSU
crystal-induced production of superoxide anions from
mouse neutrophils and macrophages at doses 100 times
lower (given by oral gavage at doses of 0.05 μmol/kg,
4 hours prior to stimulation) than those required for in-
hibition of neutrophil infiltration (oral gavage at
5 μmol/kg) [30]. This suggests that colchicine at the
doses administered in this RCT may counter inflamma-
tion through antioxidant effects related to inhibition of
superoxide anion. The effectiveness of colchicine in KOA
Figure 2 Schematic diagram showing interaction of osteoarthritis (OA) and uric acid. Adapted from Denoble et al. [6] Figure legends: In this
model, osteoarthritis (OA) leads to release of uric acid and proteoglycans, which enucleate to form microparticles. Hyperuricemia further increases
diffusion of uric acid into joint fluid from blood, contributing to constitutive sub-acute inflammation and progression of OA via inflammasome
activation. IL, Interleukin; KOA, knee osteoarthritis.
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these RCT was done in subjects with signs of knee inflam-
mation, while the other two were among subjects with pri-
mary KOA [7-9]. The main limitations in these RCTs
include single-centered studies with small sample sizes.
One study was in a subgroup of patients who had signifi-
cant knee effusions who received intra-articular cortico-
steroids, thus limiting its generalizability [7]. Two studies
did not use standardized outcome measures [7,9], and in
all studies, the underlying mechanism of colchicine on
KOA were not evaluated. The long-term safety profile of
colchicine is well known based on its traditional use as a
treatment for gout, its evaluation in clinical trials used for
marketing approval of colchicine for gout [31], and its use
as the standard first line and long-term treatment for FMF
[32-34]. An additional recent RCT, evaluating colchicine
at 0.5 mg/day for 3 years in addition to statins and stand-
ard therapies, appeared effective for the prevention of car-
diovascular events in participants with stable coronary
disease and also demonstrated an excellent safety profile
[35]. Apart from the US, another distinct advantage of col-
chicine is its availability as generic medication. If thisproof of concept study is successful, it may potentially
benefit a large OA patient population at an affordable
price.
There are a few limitations of this study. The develop-
ment of disease-modifying osteoarthritis drugs (DMOADs)
is faced with many challenges [4]. For instance, the
current FDA guidelines define the current acceptable
structural endpoint for DMOAD clinical trials as a
slowing in the loss of knee joint space narrowing (JSN)
using radiographs, which in addition, would need to be
accompanied by symptom improvement [36]. Although
we may break new ground in understanding the under-
lying mechanism of colchicine and clinical response to
colchicine treatment in the COLKOA trial, there is no
structural endpoint in this study appropriate for meeting
the guideline criteria for DMOAD. Nevertheless, this
study will provide valuable information regarding the jus-
tification for a subsequent larger multi-center DMOAD
trial with structural endpoints and insights into study de-
sign. Other limitations include the use of frequent and
moderate knee pain as a recruitment criterion, which may
inflate response rates in both treatment and placebo
Leung et al. Trials  (2015) 16:200 Page 10 of 11groups due to regression to the mean. However, patients
with higher pain scores constitute the population of inter-
est and randomization ensures that there will be no sys-
tematic difference between the arms other than treatment
versus placebo.
In summary, KOA is disabling and is increasingly
prevalent. A DMOAD treatment to relieve symptoms
and progression is urgently needed. Colchicine has the-
oretical and some clinical evidence of benefit in subjects
with KOA. It has a good safety profile and is practical
for long term use. The COLKOA trial will stringently
test its clinical efficacy and underlying mechanism of ac-
tion. This will potentially provide a new and affordable
treatment for KOA.
Trial status
ClinicalTrials.gov Identifier: NCT02176460. Recruitment
for this trial started in October 2013. As of December
2014, 83 participants have been recruited and 61
participants have completed the trial protocol. At the
time of manuscript submission, recruitment and follow-
up of patients is in progress.
Additional file
Additional file 1: Table S1. Drugs that interact negatively with
colchicine [12].
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